Show simple item record

dc.contributor.advisorÖzçelik, Tayfun
dc.contributor.authorSevinç, Akın
dc.date.accessioned2016-07-01T10:58:30Z
dc.date.available2016-07-01T10:58:30Z
dc.date.issued2003
dc.identifier.urihttp://hdl.handle.net/11693/29362
dc.descriptionCataloged from PDF version of article.en_US
dc.description.abstractRNASEL (MIM# 180435) encodes for the ubiquitously expressed ribonuclease L (RNase L), which mediates the antiviral and pro-apoptotic activities of the 2-5A system. Recently, RNASEL Arg462Gln (G1385A) variant is shown to be implicated in up to 13% of prostate cancer cases. Furthermore, RNASEL mutations segregating with disease within hereditary prostate cancer (HPC) families, and loss of heterozygosity (LOH) in tumor tissues have been reported. RNase L has been proposed to suppress the development of cancer through its ability to degrade RNA and initiate a cellular stress that leads to apoptosis. Analysis for allelic losses at the long arm of the chromosome 1 suggested that inactivation of a gene(s) on 1q23-32, which encompasses the RNASEL locus, might contribute to the genesis of breast cancer. Based on chromosomal location and function of RNASEL, and pleitropic effects of cancer associated mutations, we south to investigate the hypothesis that Arg462Gln variant of RNASEL is associated with breast cancer risk. The homozygote mutant (odds ratio (OR) = 0.75, 95% CI= 0.49- 1.14), heterozygote (OR=1.02, 95% CI= 0.76-1.37), or the genotype having at least one mutant allele (OR= 0.94, 95% CI=0.72-1.24) was found to be not associated with the breast cancer risk. The adjustment of the data with age, menopausal, smoking status, body-mass-index, age at menarche, age of 1st pregnancy, number of children, and family history of breast cancer did not change the results (homozygote mutant (OR= 0.72, 95% CI= 0.46-1.12), heterozygote (OR= 0.95, 95% CI= 0.70-1.29), or genotype having at least one mutant allele (OR= 0.89, 95% CI= 0.66-1.18)). In conclusion, our study reports no association between the RNASEL G1385A variant and breast cancer risk.en_US
dc.description.statementofresponsibilitySevinç, Akınen_US
dc.format.extentxiv, 128 leaves, illustrations, tables, graphs, 30 cmen_US
dc.language.isoEnglishen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject.lccWP870 .S48 2003en_US
dc.subject.lcshBreast Cancer.en_US
dc.titleRNASEL G1385A variant and breast cancer susceptibilityen_US
dc.typeThesisen_US
dc.departmentDepartment of Moleculer Biologyen_US
dc.publisherBilkent Universityen_US
dc.description.degreeM.S.en_US
dc.identifier.itemidBILKUTUPB072052


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record